
51 - 200 employees
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for womenβs cancers. Our lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. We are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. For more information about the company please visit www.olema.com.
π₯ 3 minutes ago
51 - 200
Senior Medical Science Liaison for Olema Oncology engaging with key opinion leaders and healthcare providers. Facilitating scientific exchange and supporting medical affairs objectives within the Southeast Region.